ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to rise, in part due to the obesity epidemic. Obese women with EC have a 6.3-fold increased risk of death from this disease, as compared to their non-obese counterparts. Patients with advanced/recurrent EC are unlikely to be cured by surgery, conventional chemotherapy (paclitaxel + carboplatin is the standard first-line treatment), radiation, or a combination of these. Thus, new treatments for EC are desperately needed as well as a better understanding

Trial Details

NCT ID
NCT05542407
Phase
PHASE1
Sponsor
UNC Lineberger Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Uterine Serous Carcinoma Uterine Cancer
Interventions
  • Atezolizumab
  • ONC201
Locations (sample)
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584

Key Eligibility Criteria

  • Ability to understand and willingness to sign a written informed consent obtained to participate in the study and HIPAA authorization for release o…
  • Age ≥ 18 years at the time of consent.
  • ECOG Performance Status of 0, 1, or 2
  • Histologically confirmed metastatic or recurrent EC (endometrioid, carcinosarcoma, serous, clear cell, adeno-squamous and mixed histologies).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Serous Carcinoma Uterine Cancer Trials on Trialify →